Royalty Pharma saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 82.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History reveals that the market's biggest winners typically have an RS Rating of over 80 as they begin their biggest price moves.
Royalty Pharma is now considered extended and out of buy range after clearing a 34.20 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
EPS growth decreased last quarter from 5,400% to -70%, but sales rose from 0% to 8%.
The company holds the No. 54 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
